Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

This study has been completed.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
NCT01319422
First received: March 14, 2011
Last updated: July 14, 2015
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2014
  Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)